CLINICAL USE


Myoclonus

DOSE IN NORMAL RENAL FUNCTION

7.2 g daily in 2–3 divided doses titrated to a maximum of 20 g daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :142.2
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :15
  • %Excreted unchanged in urine &nbsp &nbsp : >90

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.7

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :5/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    50–80 4.8 g in 2–3 divided doses30–50 1.2 g twice daily20–30 1.2 g daily<20

  • Contraindicated

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Likely dialysability. Avoid.
  • Contraindicated
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Avoid.
  • Contraindicated
  • HDF/high flux &nbsp :Dialysed. Avoid.
  • Contraindicated
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR=20–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt